Schedule 13G Filing for Olema Pharmaceuticals, Inc.

This filing details the beneficial ownership of Olema Pharmaceuticals, Inc. common stock as of March 16, 2026. Invus Public Equities, L.P. directly holds 3,898,500 shares, representing 4.5% ownership. Due to general partnership and management roles, Invus Public Equities Advisors, LLC, Invus Global Management, LLC, Siren, L.L.C., and Mr. Raymond Debbane are also deemed beneficial owners of these shares. Additionally, Avicenna Life Sci Master Fund LP directly holds 563,449 shares (0.6% ownership), with Avicenna Life Sci Master GP LLC, Ulys, L.L.C., and Mr. Raymond Debbane also deemed beneficial owners of these shares through their respective roles. Mr. Raymond Debbane, in total, may be deemed the beneficial owner of 4,461,949 shares, representing 5.1% of the outstanding stock. The filing confirms these securities were not acquired or held for the purpose of changing or influencing control of the issuer.